Mohamed Hassanein
Research Subjects
Research Interests
Mohamed Hassanein has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Alok Pandey
PBL Assay Science
2 shared publications - Amanda Hays
BioAgilytix Labs
2 shared publications - Carmen Fernández-Metzler
PharmaCadence Analytical Services, LLC
2 shared publications - Jennifer Green
Takeda Development Center Americas, Inc
2 shared publications - Karen J. Quadrini
Prothena Biosciences Inc, Brisbane, CA 94005, USA
2 shared publications - Lakshmi Amaravadi
AstraZeneca, Waltham, USA
2 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70562
Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment
Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their utility in routine monitoring and clinical trials. Blood‐based biomarkers offer a complementary approach, providing minimally invasive, readily accessible measures that can be repeatedly sampled over time. Emerging blood‐derived signatures, including gene expression profiles and circulating molecular inflammation scores, capture systemic immune activity and have shown promise in predicting treatment response, disease flares, and pharmacodynamic (PD) effects of therapies. Recent advances utilizing multi‐omics technologies and machine learning methods have further improved the predictive performance of blood‐based biomarkers, particularly in the context of biologic therapies such as anti–tumor necrosis factor agents. Despite these advances and growing promises, challenges related to validation, standardization, and clinical integration persist. This review focused on recent advances in blood‐based biomarkers for IBD, with an emphasis on their use in predicting treatment response and assessing pharmacodynamic effects in clinical trials.
- 27 April 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70562
Open AccessAdvancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment
Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their utility in routine monitoring and clinical trials. Blood‐based biomarkers offer a complementary approach, providing minimally invasive, readily accessible measures that can be repeatedly sampled over time. Emerging blood‐derived signatures, including gene expression profiles and circulating molecular inflammation scores, capture systemic immune activity and have shown promise in predicting treatment response, disease flares, and pharmacodynamic (PD) effects of therapies. Recent advances utilizing multi‐omics technologies and machine learning methods have further improved the predictive performance of blood‐based biomarkers, particularly in the context of biologic therapies such as anti–tumor necrosis factor agents. Despite these advances and growing promises, challenges related to validation, standardization, and clinical integration persist. This review focused on recent advances in blood‐based biomarkers for IBD, with an emphasis on their use in predicting treatment response and assessing pharmacodynamic effects in clinical trials.
- 2 January 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (1) , 91-109
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
Pharmacodynamic (PD) biomarkers provide crucial insights into a drug's mechanism of action (MoA) and efficacy by measuring its effects on biological targets within an organism. PD biomarkers can be proximal (e.g. receptor occupancy, enzyme inhibition) or distal (e.g. downstream pathway modulation) to the biological target. In drug development, PD biomarkers are essential for monitoring patient response, assessing therapeutic efficacy, optimizing dosage strategies, and streamlining the drug development process by informing go/no-go decisions. In personalized medicine, PD biomarkers enable tailored treatments based on individual responses, enhancing both effectiveness and safety. Sound bioanalytical strategies and rigorous assay validation practices are key for successful integration of PD biomarkers into clinical trials. This paper outlines the bioanalytical and assay considerations for developing and validating informative PD biomarker assays and their use in drug development.
- 2 January 2026
- Published by Taylor & Francis in Bioanalysis
- Vol. 18 (1) , 91-109
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
Pharmacodynamic (PD) biomarkers provide crucial insights into a drug's mechanism of action (MoA) and efficacy by measuring its effects on biological targets within an organism. PD biomarkers can be proximal (e.g. receptor occupancy, enzyme inhibition) or distal (e.g. downstream pathway modulation) to the biological target. In drug development, PD biomarkers are essential for monitoring patient response, assessing therapeutic efficacy, optimizing dosage strategies, and streamlining the drug development process by informing go/no-go decisions. In personalized medicine, PD biomarkers enable tailored treatments based on individual responses, enhancing both effectiveness and safety. Sound bioanalytical strategies and rigorous assay validation practices are key for successful integration of PD biomarkers into clinical trials. This paper outlines the bioanalytical and assay considerations for developing and validating informative PD biomarker assays and their use in drug development.
- Open Access
- 30 September 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-4
Why is Biomarker Assay Validation Different from that of Pharmacokinetic Assays?
- 30 September 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-4
Open AccessWhy is Biomarker Assay Validation Different from that of Pharmacokinetic Assays?